News & Events

01 March 2019 Board Appointment

OMEGA DIAGNOSTICS GROUP PLC (“Omega” or the “Company” or the “Group”) Omega (AIM: ODX), the medical diagnostics company focused on allergy, food intolerance and infectious disease, announces the appointment of Jeremy Millard as Non-Executive Director to the Board with immediate effect, after a thorough search process. The Board consider Jeremy to be independent and it is anticipated that he will, in due course, be appointed to the Audit and Remuneration Committees of the Company. Jeremy has 20 years investment banking experience and was previously a partner at Smith Square Partners LLP where he provided strategic and corporate advice to clients in the science, technology and telecommunications sectors, prior to which he headed up the technology practice at Rothschild in London. Jeremy is currently a Non-Executive Director and chairman of the audit committee of AIM-listed Idox plc and a Non-Executive Director of AIM-listed Ilika Plc. Bill Rhodes, Interim Non ...

Read the rest of entry »

20 April 2018 Allersys Distribution Agreement

Omega announces that it has signed a global distribuon agreement with Immunodiagnostic Systems Limited for its Allersys® range of allergy assays.

Click here to read the full article.

Omega Diagnostics and Burnet Institute announce VISITECT® CD4 CE-Marking

Omega Diagnostics, the medical diagnostics company focused on allergy, food intolerance and infectious disease, is delighted to announce it has successfully achieved CE-Marking of its VISITECT® CD4 test for supporting the management of people living with HIV, following successful performance evaluations in India and the UK. VISITECT® CD4, co-developed with the Burnet Institute, is the world’s first instrument-free and affordable rapid test for determining CD4 threshold in people living with HIV. It is designed for use at the point-of-care and provides a means for decentralisation of CD4 testing capacity to where it is most needed. VISITECT® CD4 will enable those patients in rural locations to access testing more easily and does not require investment in equipment or highly technical scientific staff to operate. The test will now go forward into further regulatory processes that are necessary before being implemented in those regions where HIV remains a significant public health chall ...

Read the rest of entry »

Pages: Previous123NextReturn Top